New York State Common Retirement Fund
EGRX

New York State Common Retirement Fund’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

New York State Common Retirement Fund’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-90
Closed -$504 – 3385
2024
Q2 		$504 Sell
90
-6,300
-99% -$27.4K ﹤0.01% 3338
2024
Q1 		$33.5K Hold
6,390
– – ﹤0.01% 3073
2023
Q4 		$33.4K Sell
6,390
-24
-0.4% -$237 ﹤0.01% 3084
2023
Q3 		$101K Sell
6,414
-8,905
-58% -$160K ﹤0.01% 2717
2023
Q2 		$298K Sell
15,319
-1,722
-10% -$40.9K ﹤0.01% 2329
2023
Q1 		$483K Sell
17,041
-9,523
-36% -$283K ﹤0.01% 2192
2022
Q4 		$776K Buy
26,564
+18,174
+217% +$578K ﹤0.01% 2100
2022
Q3 		$222K Buy
8,390
+13
+0.2% +$477 ﹤0.01% 2733
2022
Q2 		$372K Sell
8,377
-28
-0.3% -$1.29K ﹤0.01% 2501
2022
Q1 		$416K Buy
8,405
+7
+0.1% +$336 ﹤0.01% 2487
2021
Q4 		$428K Sell
8,398
-32
-0.4% -$1.66K ﹤0.01% 2514
2021
Q3 		$470K Sell
8,430
-2,154
-20% -$106K ﹤0.01% 2501
2021
Q2 		$453K Buy
10,584
+84
+0.8% +$3.47K ﹤0.01% 2657
2021
Q1 		$438K Sell
10,500
-1,100
-9% -$51.1K ﹤0.01% 2519
2020
Q4 		$540K Hold
11,600
– – ﹤0.01% 2316
2020
Q3 		$493K Hold
11,600
– – ﹤0.01% 2221
2020
Q2 		$557K Buy
11,600
+2,100
+22% +$105K ﹤0.01% 2151
2020
Q1 		$437K Hold
9,500
– – ﹤0.01% 2114
2019
Q4 		$571K Hold
9,500
– – ﹤0.01% 2235
2019
Q3 		$537K Sell
9,500
-11,075
-54% -$623K ﹤0.01% 2294
2019
Q2 		$1.15M Buy
20,575
+5,939
+41% +$310K ﹤0.01% 1946
2019
Q1 		$739K Hold
14,636
– – ﹤0.01% 2119
2018
Q4 		$590K Sell
14,636
-56,997
-80% -$2.94M ﹤0.01% 2200
2018
Q3 		$4.97M Buy
71,633
+8,422
+13% +$638K 0.01% 1272
2018
Q2 		$4.78M Sell
63,211
-1,256
-2% -$79K 0.01% 1281
2018
Q1 		$3.4M Buy
64,467
+2,234
+4% +$130K ﹤0.01% 1372
2017
Q4 		$3.32M Buy
62,233
+11,213
+22% +$624K ﹤0.01% 1397
2017
Q3 		$3.04M Sell
51,020
-483
-0.9% -$29.2K ﹤0.01% 1423
2017
Q2 		$4.06M Buy
51,503
+15,002
+41% +$1.23M 0.01% 1354
2017
Q1 		$3.03M Buy
36,501
+19,034
+109% +$1.42M ﹤0.01% 1464
2016
Q4 		$1.39M Buy
17,467
+8,067
+86% +$586K ﹤0.01% 1878
2016
Q3 		$658K Buy
9,400
+500
+6% +$27.7K ﹤0.01% 2188
2016
Q2 		$345K Hold
8,900
– – ﹤0.01% 2450
2016
Q1 		$360K Sell
8,900
-3,134
-26% -$199K ﹤0.01% 2397
2015
Q4 		$1.07M Buy
12,034
+600
+5% +$47.4K ﹤0.01% 1934
2015
Q3 		$846K Buy
11,434
+2,530
+28% +$210K ﹤0.01% 2041
2015
Q2 		$720K Buy
8,904
+6,093
+217% +$397K ﹤0.01% 2360
2015
Q1 		$118K Buy
+2,811
New +$79.7K ﹤0.01% 2210

Other funds holding EGRX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

New York State Common Retirement Fund's EGRX Position: Q3 2024 in Review

New York State Common Retirement Fund sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2024, closing a stake of 90 shares — an estimated $504 sold.

New York State Common Retirement Fund first reported a position in EGRX in Q1 2015 and held it in 38 quarters. The position peaked at $4.97M in Q3 2018. 65 funds tracked by Wall St. Rank hold EGRX as of Q3 2024.

  • New York State Common Retirement Fund reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
  • New York State Common Retirement Fund sold 90 Eagle Pharmaceuticals, Inc. shares in Q3 2024, an estimated $504.
  • New York State Common Retirement Fund first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 38 quarters.
  • New York State Common Retirement Fund's Eagle Pharmaceuticals, Inc. position peaked at $4.97M in Q3 2018.
  • 65 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2024.

Based on New York State Common Retirement Fund's 13F filing for Q3 2024, filed 28 Oct 2024.